# A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

> **NCT06430437** · PHASE3 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer With HER2- Mutations

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin

## Key facts

- **NCT ID:** NCT06430437
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-29
- **Primary completion:** 2026-02
- **Final completion:** 2027-04
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06430437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06430437, "A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06430437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*